modelFondaparinux
Extends from Pharmacolibrary.Drugs.ATC.B.B01AX05.
Information
| name: | Fondaparinux | |
| ATC code: | B01AX05 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 7.5 | mg |
| volume of distribution: | 7.2 | L |
| clearance: | 0.18 | L/h |
| other parameters in model implementation | ||
Fondaparinux is a synthetic pentasaccharide anticoagulant that selectively inhibits Factor Xa via antithrombin III. It is used for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly after orthopedic surgery. Fondaparinux is approved and currently used in clinical practice.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers after subcutaneous administration.
References
Hanada, K, et al., & Takahashi, H (2018). Population pharmacokinetics and pharmacodynamics of fondaparinux in Japanese patients after artificial total knee replacement . International journal of clinical pharmacology and therapeutics 56(6) 255–262. DOI:10.5414/CP203169 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29595122
Bauer, KA, et al., & Meuleman, DG (2002). Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovascular drug reviews 20(1) 37–52. DOI:10.1111/j.1527-3466.2002.tb00081.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12070533
Gerotziafas, GT, et al., & Elalamy, I (2014). New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Therapeutics and clinical risk management 10 423–436. DOI:10.2147/TCRM.S49063 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24966680
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)